These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33190687)

  • 1. Anti-pan-neurofascin IgM in COVID-19-related Guillain-Barré syndrome: Evidence for a nodo-paranodopathy.
    Tard C; Maurage CA; de Paula AM; Cassim F; Delval A; Kuchcinski G; Davion JB; Defebvre L; Bouchiba M; ; Jourdain M; Boucraut J
    Neurophysiol Clin; 2020 Oct; 50(5):397-399. PubMed ID: 33190687
    [No Abstract]   [Full Text] [Related]  

  • 2. Nodal proteins are target antigens in Guillain-Barré syndrome.
    Devaux JJ; Odaka M; Yuki N
    J Peripher Nerv Syst; 2012 Mar; 17(1):62-71. PubMed ID: 22462667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Motor Axonal Neuropathy Related to COVID-19 Infection: A New Diagnostic Overview.
    Petrelli C; Scendoni R; Paglioriti M; Logullo FO
    J Clin Neuromuscul Dis; 2020 Dec; 22(2):120-121. PubMed ID: 33214404
    [No Abstract]   [Full Text] [Related]  

  • 4. Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy.
    Delmont E; Manso C; Querol L; Cortese A; Berardinelli A; Lozza A; Belghazi M; Malissart P; Labauge P; Taieb G; Yuki N; Illa I; Attarian S; Devaux JJ
    Brain; 2017 Jul; 140(7):1851-1858. PubMed ID: 28575198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guillain-Barré Syndrome with Facial Diplegia Related to SARS-CoV-2 Infection.
    Chan JL; Ebadi H; Sarna JR
    Can J Neurol Sci; 2020 Nov; 47(6):852-854. PubMed ID: 32468972
    [No Abstract]   [Full Text] [Related]  

  • 6. Guillain-Barré syndrome associated with SARS-CoV-2 infection. Comments after 16 published cases.
    Guijarro-Castro C; Rosón-González M; Abreu A; García-Arratibel A; Ochoa-Mulas M
    Neurologia (Engl Ed); 2020; 35(6):412-415. PubMed ID: 32565036
    [No Abstract]   [Full Text] [Related]  

  • 7. Subacute nodopathy with conduction blocks and anti-neurofascin 140/186 antibodies: an ultrastructural study.
    Vallat JM; Mathis S; Magy L; Bounolleau P; Skarzynski M; Heitzmann A; Manso C; Devaux J; Uncini A
    Brain; 2018 Jul; 141(7):e56. PubMed ID: 29800077
    [No Abstract]   [Full Text] [Related]  

  • 8. Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature.
    Scheidl E; Canseco DD; Hadji-Naumov A; Bereznai B
    J Peripher Nerv Syst; 2020 Jun; 25(2):204-207. PubMed ID: 32388880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Case of Guillain-Barré Syndrome Associated With COVID-19.
    Rajdev K; Victor N; Buckholtz ES; Hariharan P; Saeed MA; Hershberger DM; Bista S
    J Investig Med High Impact Case Rep; 2020; 8():2324709620961198. PubMed ID: 32981333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post SARS-CoV-2 Guillain-Barré syndrome.
    Arnaud S; Budowski C; Ng Wing Tin S; Degos B
    Clin Neurophysiol; 2020 Jul; 131(7):1652-1654. PubMed ID: 32422529
    [No Abstract]   [Full Text] [Related]  

  • 11. [SARS-CoV-2, a new causal agent of Guillain-Barre syndrome].
    Redondo-Urda MJ; Rodríguez-Peguero FJ; Pérez-Gil O; Del Valle-Sánchez M; Carrera-Izquierdo M
    Rev Neurol; 2020 Oct; 71(7):275-276. PubMed ID: 32959360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-neurofascin autoantibody and demyelination.
    Kira JI; Yamasaki R; Ogata H
    Neurochem Int; 2019 Nov; 130():104360. PubMed ID: 30582947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guillain-Barré Syndrome Associated with SARS-CoV-2.
    Toscano G; Palmerini F; Ravaglia S; Ruiz L; Invernizzi P; Cuzzoni MG; Franciotta D; Baldanti F; Daturi R; Postorino P; Cavallini A; Micieli G
    N Engl J Med; 2020 Jun; 382(26):2574-2576. PubMed ID: 32302082
    [No Abstract]   [Full Text] [Related]  

  • 14. SARS-CoV-2-Associated Guillain-Barre Syndrome With Good Response to Plasmapheresis.
    Granger A; Omari M; Jakubowska-Sadowska K; Boffa M; Zakin E
    J Clin Neuromuscul Dis; 2020 Sep; 22(1):58-59. PubMed ID: 32833726
    [No Abstract]   [Full Text] [Related]  

  • 15. SARS-CoV-2-associated Guillain-Barré syndrome with dysautonomia.
    Su XW; Palka SV; Rao RR; Chen FS; Brackney CR; Cambi F
    Muscle Nerve; 2020 Aug; 62(2):E48-E49. PubMed ID: 32445201
    [No Abstract]   [Full Text] [Related]  

  • 16. Guillain-Barré syndrome related to COVID-19 infection.
    Alberti P; Beretta S; Piatti M; Karantzoulis A; Piatti ML; Santoro P; Viganò M; Giovannelli G; Pirro F; Montisano DA; Appollonio I; Ferrarese C
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32350026
    [No Abstract]   [Full Text] [Related]  

  • 17. HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome.
    Gigli GL; Vogrig A; Nilo A; Fabris M; Biasotto A; Curcio F; Miotti V; Tascini C; Valente M
    Neurol Sci; 2020 Dec; 41(12):3391-3394. PubMed ID: 33006723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guillain-Barré syndrome after covid-19 infection.
    García-Manzanedo S; López de la Oliva Calvo L; Ruiz Álvarez L
    Med Clin (Barc); 2020 Oct; 155(8):366. PubMed ID: 32718718
    [No Abstract]   [Full Text] [Related]  

  • 19. Axonal Guillain-Barré syndrome: concepts and controversies.
    Kuwabara S; Yuki N
    Lancet Neurol; 2013 Dec; 12(12):1180-8. PubMed ID: 24229616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing.
    Dalakas MC
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32518172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.